Cell Therapeutics spins off new protein tech company

Cell Therapeutics is spinning off its protein technology into a new company that it eventually would like to see go public. Aequus BioPharma will take the company's intellectual property that extends the life of proteins without the chemical alteration that's needed now. Dropping that step will cut their cost and add to the value of the product. Former Immunex executives in Seattle are being recruited for the new company, which will start out with about $1.5 million to $2 million in seed funding.

- read the Seattle Post-Intelligencer report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.